CSL (ASX:CSL) has entered into an exclusive partnership with Alentis Therapeutics to co-develop lixudebart, supporting the antibody with a US$355 million upfront payment and up to US$1.2 billion in potential milestone payments.
CSL shares have been on a strong run recently, with the 90 day share price return of 44.98% and 30 day share price return of 5.09% suggesting momentum has picked up after a weaker patch. This comes even though the 1 year total shareholder return is still down 9.23% and the 5 year total shareholder return has fallen 32.74%.
Seize this CSL nephrology catalyst as a starting point to review other specialised healthcare opportunities in our curated list of 8 healthcare AI stocks.CSL has just committed serious capital to lixudebart, and the share price has already risen significantly over the past 90 days. Investors may now be weighing whether to pay up for that momentum or wait for a calmer entry as the valuation work comes into focus.
Most Popular Narrative: 13.3% Undervalued
CSL is trading at A$181.99, while the most followed narrative on the stock points to a fair value of A$210. That gap frames how investors might read the lixudebart deal and the recent share price surge.
CSL is one of Australia’s highest-quality businesses and has a long history of delivering strong returns. It is a global leader in plasma therapies, vaccines and biotechnology, with products that are difficult to replicate and protected by strict regulation. Healthcare demand tends to remain resilient regardless of economic conditions.
See why 41 investors see CSL as 13% undervalued.
According to danmad, the narrative behind that fair value leans heavily on CSL's leadership in plasma therapies and vaccines, as well as the high barriers to entry created by decades of scientific expertise and tight regulation. Those features are presented as reasons the business can keep investing heavily in areas like nephrology and rare disease without relying on rapid economic growth to support demand.
The same narrative flags trade offs that matter for anyone looking at CSL after the recent run. For example, the shares are often described as trading at a premium, and the growth story is closely linked to successful product development and regulatory approvals. This can introduce timing risk around new therapies like lixudebart. Currency movements are also highlighted as a swing factor for reported earnings, given CSL's global revenue mix.
In that context, the lixudebart partnership fits alongside CSL's stated aim to keep building out therapies in immunology, haematology and rare diseases, while integrating the Vifor kidney care business. The narrative assumes heavy ongoing investment in research, plasma collection and manufacturing efficiency. This feeds into the discount rate of 7.50% used to reach the A$210 assessment.
Result: Fair Value of A$210 (UNDERVALUED)
Still, CSL’s narrative could be shaken if regulatory outcomes on new therapies disappoint or if integration work at CSL Vifor drags on operational performance.
Find out about the key risks to this CSL narrative.
Next Steps
Sentiment on CSL is mixed, with fresh enthusiasm around lixudebart set against past share price weakness and flagged risks. Act quickly, review the numbers, and judge the balance for yourself with 3 key rewards and 1 important warning sign.
Looking for more CSL-linked investment ideas?
Do not stop at CSL. Broaden your watchlist with other clear stories where the numbers and business quality line up in ways you can actually compare.
- Target resilience by focusing on balance sheets that look built for stress using our list of solid balance sheet and fundamentals (12 results).
- Hunt for mispriced quality where fundamentals and valuation both work in your favour with the 5 high quality undervalued stocks.
- Prioritise financial strength and future potential in under-the-radar opportunities through the 15 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com